Revolutionary Japanese Capsule Hotel “The Millennials” Brings Its Upscale Capsule Concept to Tokyo

TOKYO, Jan. 24, 2018 /PRNewswire/ — Global Agents has just announced the Grand Opening of the second in its luxury capsule hotel brand ‘The Millennials‘ for March 15th, 2018. Following the huge success of their first iteration, opened last year in Kyoto, and attracting the attention from many overseas guests and medias, Global Agents is finally bringing its brand to the Japanese capital with a first location in the bustling Shibuya district. With a new concept based on “Living in the future”, The Millennials re-imagines the capsule hotel concept through high-tech facilities and technology and social spaces to bring a formerly utilitarian concept into the realm of semi-luxury. With over 120 multi-functional Smart-Pod units spread over 5 floors of prime Shibuya real-estate, The Millennials provides guests with full control of their personal unit through the integrated iPod touch provided at check-in. These controls correspond to several unique functions, including an alarm system based on bed movement and optional projectors that make use of each unit’s built-in privacy screens. Additionally, the 3rd and 4th floor lobby doubles as a spacious coworking space for local entrepreneurs, with full office amenities, banquet & event space, and a lively “Happy Hour” with endless free beer.

The central focus of guests’ experience of The Millennials is its high-tech Smart-Pods, controlled through an in-house app that centralizes all the functions of each guest’s sleeping arrangements. With this intuitive tool, guests can adjust lighting, air-flow, and even the incline of their mattress easily. Of particular note is the unique, soundless alarm system slowly raises guests to a seated position along with steadily brighter lights, enabling guests to wake up bright and early without disturbing their neighbors. For pods equipped with projectors, guests can connect their personal devices to watch any of their favorite programming in their own private theater. Each unit comes with underbed storage for luggage and can be locked for those staying consecutive nights. Every floor also includes completely private individual shower booths for guests, and free Wi-Fi throughout.

The 4th floor lobby of the complex doubles as a stylish lounge specially designed for guests to interact with each other, and a common kitchen to cook simple meals during their stay. The 3rd floor offers a large and colorful coworking space that can also be used for banquet and events. With an open-concept design, this area focuses on encouraging interaction between travelers and local entrepreneurs. All users of this community space have free access to unlimited coffee, and a daily happy hour provides free draft beer every day from 5:30 p.m. to 6:30 p.m.

The Millennials is the latest hotel from Japanese developer Global Agents, whose CEO Takeshi Yamasaki notes that “our goal with The Millennials is to go beyond what people have come to expect from this type of hotel, and create a new option for today’s customer who wants both affordability and style.” Global Agents has seen great success in the Tokyo market with their Social Apartment brand of co-living arrangements and plans to open several new lifestyle hotels across Japan this year, and much more to come in 2019!

For more information, contact:
Zacharie Coskun
z-coskun@global-agents.co.jp
+81-3-6433-5792

Related Images

image1.jpg
The Millennials Shibuya Grand Opening!

image2.jpg
Social Area

image3.jpg
Coworking & Event Space

image4.jpg
Smart-Pod

Related Links

The Millennials Shibuya Official Website

The Millennials Shibuya Instragram Account

Related Video

http://www.youtube.com/watch?v=Z57NPPDRGJ4

SOURCE Global Agents

Genesis Philanthropy Group Awards More Than $7 Million to its Partners in North America, Israel, United Kingdom, Europe and the former Soviet Union

NEW YORK, Jan. 24, 2018 /PRNewswire/ — Genesis Philanthropy Group (GPG), the premier global foundation fostering Jewish identity among Russian-speaking Jews, announced that it is awarding its first round of grants in 2018, totaling more than $7 million, to a number of leading international and local Jewish organizations.

“We are thrilled to support Genesis Philanthropy Group as it spearheads the growth of programs enriching Jewish identity and connection around the world,” said Mikhail Fridman, an international businessman, investor and philanthropist, and a co-founder of Genesis Philanthropy Group. “We have no doubt that our partnerships with top global Jewish organizations will lead a growing number of young Jews to reconnect to world Jewry and contribute to the advancement of Jewish communities and Jewish culture.”

Among organizations receiving major funding are:

  • Taglit-Birthright Israel – to support its efforts to bring 5,000 Russian-speaking participants from the former Soviet Union and Germany to Israel and help improve their experiences through enhanced programming rooted in heritage exploration and cultural engagement;
  • Brown University – to support its newly established Israel fund and strengthen peer-to-peer relationships between Brown University’s students and faculty and their Israeli counterparts;
  • Hillel International – to expand contact with Jewish students across the globe, wherever Russian-speaking Jewish students attend universities that have a Hillel presence. This year, the Hillel/Genesis partnership will cover the United States, Canada, Germany, Israel and at least six countries of the former Soviet Union;
  • Friends of the IDF – to further its partnership with GPG in strengthening identity-building programs for Russian-speaking soldiers and officers in the IDF.

The latest grants approved by GPG also include support to Jewish federations’ leadership-development programs and programming for families with young children in Los Angeles and Chicago, community-building initiatives of young adults in Germany through the Jewish Agency’s grassroots network, MASA ID educational travel programs in Israel and the completion of the feature film Anna’s War, which depicts the remarkable story of a six-year-old survivor whose entire family perished in the Shoah in the former Soviet Union.

“Following several years of systematic investment, we are expanding our work to strengthen Jewish identity among Russian-speaking Jews worldwide,” said Ilia Salita, president and CEO of Genesis Philanthropy Group. “We look forward to seeing the growth of these programs, which challenge and inspire Russian-speaking Jews, each in their own way, to engage in communal life and explore their heritage.”

This announcement follows news of the expansion of GPG’s funding in the United Kingdom, which reaches under-served and under-engaged Jewish communities in London and beyond through Moishe House and PJ Library, programs geared toward students and families.

ABOUT GENESIS PHILANTHROPY GROUP
Genesis Philanthropy Group (GPG) is a global foundation, co-founded by Mikhail Fridman, an international businessman, investor and philanthropist, and his business partners. GPG primarily, but not exclusively, focuses its philanthropic support on developing and enhancing Jewish identity among Russian-speaking Jews worldwide. To learn more, visit www.gpg.org.

Cision View original content:http://www.prnewswire.com/news-releases/genesis-philanthropy-group-awards-more-than-7-million-to-its-partners-in-north-america-israel-united-kingdom-europe-and-the-former-soviet-union-300587952.html

SOURCE Genesis Philanthropy Group

Related Links

http://www.gpg.org

Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)

NEW YORK, Jan. 24, 2018 /PRNewswire/ — This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the “Fund”) with information regarding the sources of the distribution to be paid on January 31, 2018 and cumulative distributions paid fiscal year-to-date.

In December 2011, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund’s long-term total return potential through regular monthly distributions declared at a fixed rate per common share. The policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund’s shares. 

The Fund’s monthly distributions may include long-term capital gains, short-term capital gains, net investment income and/or return of capital for federal income tax purposes. Return of capital includes distributions paid by the Fund in excess of its net investment income and net realized capital gains and such excess is distributed from the Fund’s assets. A return of capital is not taxable; rather, it reduces a shareholder’s tax basis in his or her shares of the Fund. In addition, distributions from the Fund’s investments in real estate investment trusts (REITs) may later be characterized as capital gains and/or a return of capital, depending on the character of the dividends reported to the Fund after year-end by REITs held by the Fund. The amount of monthly distributions may vary depending on a number of factors, including changes in portfolio and market conditions.

At the time of each monthly distribution, information will be posted to cohenandsteers.com and mailed to shareholders in a concurrent notice. However, this information may change at the end of the year because the final tax characteristics of the Fund’s distributions cannot be determined with certainty until after the end of the calendar year. Final tax characteristics of all of the Fund’s distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year-to-date from the sources indicated. All amounts are expressed per common share.

DISTRIBUTION ESTIMATES

January 2018

YEAR-TO-DATE (YTD)

January 31, 2018*

Source

Per Share Amount

% of Current Distribution

Per Share Amount

% of 2018 Distributions

Net Investment Income

$0.0029

3.63%

$0.0029

3.63%

Net Realized Short-Term Capital Gains

$0.0000

0.00%

$0.0000

0.00%

Net Realized Long-Term Capital Gains

$0.0500

62.50%

$0.0500

62.50%

Return of Capital (or other Capital Source)

$0.0271

33.87%

$0.0271

33.87%

Total Current Distribution

$0.0800

100.00%

$0.0800

100.00%

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy. The Fund estimates that it has distributed more than its income and capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’. The amounts and sources of distributions reported in this Notice are only estimates, are likely to change over time, and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The amounts and sources of distributions year-to-date may be subject to additional adjustments.

*THE FUND WILL SEND YOU A FORM 1099-DIV FOR THE CALENDAR YEAR THAT WILL TELL YOU HOW TO REPORT THESE DISTRIBUTIONS FOR FEDERAL INCOME TAX PURPOSES.

The Fund’s Year-to-date Cumulative Total Return for fiscal year 2017 (January 1, 2017 through December 31, 2017) is set forth below. Shareholders should take note of the relationship between the Year-to-date Cumulative Total Return with the Fund’s Cumulative Distribution Rate for 2018. In addition, the Fund’s Average Annual Total Return for the five-year period ending December 31, 2017 is set forth below. Shareholders should note the relationship between the Average Annual Total Return with the Fund’s Current Annualized Distribution Rate for 2018. The performance and distribution rate information disclosed in the table is based on the Fund’s net asset value per share (NAV). The Fund’s NAV is calculated as the total market value of all the securities and other assets held by the Fund minus the total liabilities, divided by the total number of shares outstanding. While NAV performance may be indicative of the Fund’s investment performance, it does not measure the value of a shareholder’s individual investment in the Fund. The value of a shareholder’s investment in the Fund is determined by the Fund’s market price, which is based on the supply and demand for the Fund’s shares in the open market.

Fund Performance and Distribution Rate Information:

Year-to-date January 1, 2017 to December 31, 2017

Year-to-date Cumulative Total Return1

8.33%

Cumulative Distribution Rate2

0.60%

Five-year period ending December 31, 2017

Average Annual Total Return3

9.94%

Current Annualized Distribution Rate4

7.16%

1.

Year-to-date Cumulative Total Return is the percentage change in the Fund’s NAV over the year-to-date time period including distributions paid and assuming reinvestment of those distributions.

2.

Cumulative Distribution Rate for the Fund’s current fiscal period (January 1, 2018 through January 31, 2018) measured on the dollar value of distributions in the year-to-date period as a percentage of the Fund’s NAV as of December 31, 2017.

3.

Average Annual Total Return represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ending December 31, 2017. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year including distributions paid and assuming reinvestment of those distributions.

4.

The Current Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV as of December 31, 2017.

Investors should consider the investment objectives, risks, charges and expense of the fund carefully before investing. You can obtain the fund’s most recent periodic reports, when available, and other regulatory filings by contacting your financial advisor or visiting cohenandsteers.com. These reports and other filings can be found on the Securities and Exchange Commission’s EDGAR Database. You should read these reports and other filings carefully before investing.

Shareholders should not use the information provided in preparing their tax returns. Shareholders will receive a Form 1099-DIV for the calendar year indicating how to report Fund distributions for federal income tax purposes.

Website: http://cohenandsteers.com/ 
Symbol: (NYSE: CNS)

About Cohen & Steers. Cohen & Steers is a global investment manager specializing in liquid real assets, including real estate securities, listed infrastructure, commodities and natural resource equities, as well as preferred securities and other income solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Hong Kong, Tokyo and Seattle.

Cision View original content:http://www.prnewswire.com/news-releases/cohen–steers-total-return-realty-fund-inc-rfi-notification-of-sources-of-distribution-under-section-19a-300587947.html

SOURCE Cohen & Steers

Related Links

http://www.cohenandsteers.com

Forbes Names Levy To #3 Spot On 2018 Best Employers For Diversity List

CHICAGO, Jan. 24, 2018 /PRNewswire/ — Levy, known for acclaimed restaurants and redefining hospitality experiences at sports and entertainment venues, earned the #3 spot in Forbes’ “Best Employers for Diversity” list for 2018, announced this week. The list honors companies that demonstrate a dedication to diversity and inclusion, and follows Levy’s inclusion in Forbes’ “America’s Best Employers” list last year.

Forbes highlighted the high number of female executives and ethnic diversity among management-level employees across Levy and its subsidiaries, E15 (technology and analytics), Curiology Group (experience design) and Rank + Rally (retail). Levy joins other major brands and food and beverage companies on the list, including Starbucks (#26), Nestle (#81), PepsiCo (#110), General Mills (#142), ConAgra Brands (#151), Coca-Cola (#180), Darden Restaurants (#212), and Whole Foods Market (#236). Northern Trust and the Smithsonian Institution joined Levy at the top of the list, while Intuit, Harvard University, Principal Financial Group, Emory University, Wegmans Food Markets, Keller Williams Realty, and AbbVie rounded out the top 10.

“It’s an honor any time you are recognized by a publication as renowned as Forbes and included among such admired and forward-thinking companies, but we are especially proud to be recognized for our commitment to building a diverse and inclusive company,” said Andy Lansing, President and CEO of Levy. “Creating and fostering a diverse and inclusive workplace is absolutely essential in making Levy a terrific place to build a career.”

In citing Levy for its commitment to developing women in leadership positions, Forbes noted that female executives make up half of Levy’s eight-person executive team, including top roles with E15, Curiology, Rank + Rally, and Levy’s restaurant group.

Forbes worked with research firm Statista to compile the definitive list of the best employers for diversity in America. Statista surveyed 30,000 U.S. employees in August 2017 to inform the list, asking questions about diversity, gender, ethnicity, sexual orientation, age, and disability. Responses among underrepresented ethnic minorities, women, and people aged 50 and older received greater weight in the ranking. Other factors Statista incorporated were the gender split of companies’ management teams and boards, and whether a company proactively communicates about diversity.

About Levy
The disruptor in defining the premium sports and entertainment dining experience, Levy is recognized as one of the fastest growing and most critically acclaimed hospitality companies. Named one of the 10 most innovative companies in sports by Fast Company magazine, Levy’s diverse portfolio includes award-winning restaurants, iconic sports and entertainment venues, and convention centers as well as the Super Bowl, Grammy Awards, PGA Championship, US Open Tennis Tournament, Kentucky Derby, and NHL, MLB, NBA All-Star Games. For more, visit www.levyrestaurants.com or follow us on Facebook, Twitter, or Instagram.

Media Contact
Kevin Memolo – Finn Partners for Levy
312-329-3985
Kevin.memolo@finnpartners.com

Cision View original content:http://www.prnewswire.com/news-releases/forbes-names-levy-to-3-spot-on-2018-best-employers-for-diversity-list-300587950.html

SOURCE Levy

Related Links

http://www.levyrestaurants.com

Record attendance, national honors highlight 2017 for Smithsonian affiliate Conner Prairie

FISHERS, Ind., Jan. 24, 2018 /PRNewswire/ — Conner Prairie, one of the most-visited outdoor history museums in the U.S., broke its all-time annual attendance record and several special event attendance records last year.

At its 2018 Annual Meeting Wednesday, the Indiana museum announced its 2017 attendance was 428,602, the highest since Conner Prairie was founded 84 years ago. That number is up 37,341 people from 2016. Visitors came from 46 U.S. states and 22 foreign countries.

Membership also grew to a record high as 8,267 families consisting of 39,332 adults and children joined Conner Prairie last year. Other milestones:

  • 21,005 people took flight in the museum’s tethered helium balloon, generating record annual revenue of $231,048
  • 123,855 people attended Kroger Symphony on the Prairie, an all-time record
  • 40,283 people attended the Headless Horseman fall festival, an all-time record
  • 11,570 guests attended three free admission days, including a record 4,757 people on President’s Day
  • 575 adult volunteers gave a combined 41,273 hours of service to the museum and 100 youth volunteers ages 10-18 gave 120 hours each throughout the year

In 2017, Conner Prairie received a national award for exhibit excellence from the American Alliance of Museums. The museum was also named one of the most-visited outdoor museums in the U.S. by Education.com, Ancestry.com, Family Living Magazine and Outdoor History Museum Forum. And Conner Prairie made international headlines when an extremely rare English Longhorn calf was born via embryo transfer at the museum.

This year, new programming and exhibit enhancements will be occurring now through the fall. One enhancement will open March 27, the first day of Conner Prairie’s 2018 outdoor season. Fort Hoosier will be a 100,000-square-foot addition to Treetop Outpost, a four-story treehouse surrounded by hands-on activity areas nestled in the woods along the White River. The new area will promote free play in nature.

Spanning more than 1,000 wooded acres in central Indiana, Conner Prairie is a Smithsonian Institute affiliate. The museum offers outdoor, historically themed destinations and indoor experiential learning spaces that combine history and art with science, technology, engineering and math to offer an authentic look into history that shapes society today.

CONTACT
Duane Brodt
Director of Public Relations
brodt@connerprairie.org

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/record-attendance-national-honors-highlight-2017-for-smithsonian-affiliate-conner-prairie-300587940.html

SOURCE Conner Prairie

Related Links

http://www.connerprairie.org

GW Pharmaceuticals und ihre US-Tochtergesellschaft Greenwich Biosciences veröffentlichen richtungsweisende Epidiolex® (Cannabidiol)-Studie in der medizinischen Fachzeitschrift “The Lancet”

LONDON und CARLSBAD, Kalifornien, January 24, 2018 /PRNewswire/ —

Erste gut kontrollierte klinische Studie mit Cannabidiol beim Lennox-Gastaut-Syndrom, einer seltenen, schweren Form der Epilepsie im Kindesalter, die schwer zu behandeln ist    

Pharmazeutische Formulierung von Cannabidiol reduziert signifikant die Häufigkeit von Sturzanfällen bei Patienten mit schlechter Anfallskontrolle trotz der Verwendung mehrerer Antiepileptika –  

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW”, “das Unternehmen” oder “der Konzern”), ein biopharmazeutisches Unternehmen, das sich auf die Entdeckung, Entwicklung und Kommerzialisierung neuartiger Therapeutika aus seiner firmeneigenen Cannabinoid-Produktplattform konzentriert, gab heute zusammen mit seiner US-Tochtergesellschaft Greenwich Biosciences bekannt, dass “The Lancet” Ergebnisse einer Phase-III-Studie mit Epidiolex® (Cannabidiol) bei Patienten mit Lennox-Gastaut-Syndrom (LGS) veröffentlicht hat.[1] Epidiolex, GWs führender Produktkandidat und das potenziell erste Produkt in einer neuen Kategorie von Antiepileptika (AEDs), ist eine pharmazeutische Formulierung von gereinigtem Cannabidiol (CBD), einem Cannabinoid ohne euphorische Nebenwirkungen, das für die Behandlung einer Reihe seltener, schwerer pädiatrischer Epilepsieerkrankungen untersucht wird. In dieser Studie reduzierte Epidiolex signifikant die monatliche Anfallshäufigkeit im Vergleich zu Placebos bei hoch therapieresistenten Patienten, wenn es eine vorhandene Behandlung ergänzte. Die Behandlung mit Epidiolex war im Allgemeinen gut verträglich, mit einem Sicherheitsprofil, das mit zuvor gemeldeten Erfahrungen übereinstimmt.

Im Dezember wurde ein Zulassungsantrag für ein neues Medikament (New Drug Application, NDA) bei der US-Arzneimittelzulassungsbehörde FDA (Food and Drug Administration) für Epidiolex zur Behandlung von LGS und des Dravet-Syndroms (einer weiteren seltenen Epilepsie-Erkrankung im Kindesalter) angenommen. Das Zieldatum gemäß dem PDUFA (Prescription Drug User Fee Act) ist der 27. Juni 2018. Es wird für den Fall der Genehmigung damit gerechnet, dass das Medikament in der zweiten Hälfte des Jahres 2018 in den USA verschreibungspflichtig erhältlich sein wird. Im Dezember 2017 wurde weiterhin ein Zulassungsantrag (MAA, Marketing Authorisation Application) bei der Europäischen Arzneimittelagentur EMA eingereicht. Eine Entscheidung wird für Anfang 2019 erwartet.

“Die Veröffentlichung dieser bahnbrechenden Studie durch The Lancet ist eine aufregende Errungenschaft und ist nach der letztjährigen Veröffentlichung im New England Journal of Medicine das zweite Mal, dass Epidiolex-Daten in einer hoch angesehenen Zeitschrift veröffentlicht wurden”, sagte Justin Gover, CEO von GW. “Diese Veröffentlichungen verdeutlichen das Potenzial von Epidiolex, den erheblichen Bedarf für die Behandlung von LGS  und dem Dravet-Syndrom zu decken, zwei sehr herausfordernden Epilepsiezuständen. Wir freuen uns auf die Zusammenarbeit mit der FDA und der EMA bei der Prüfung unserer Zulassungsanträge für Epidiolex. Wir haben uns unbedingt zum Ziel gesetzt, dieses wichtige neue Therapiepotenzial den entsprechenden Patienten und ihren Betreuern schnellstmöglich zur Verfügung zu stellen.

LGS ist eine seltene, lebenslange Form der Epilepsie, die bereits im Kindesalter beginnt und mit einer hohen Sterblichkeitsrate[2] und erheblichen Entwicklungsverzögerungen einhergeht.[3],[4] LGS-Patienten leiden unter mehreren Arten von Anfällen, einschließlich Sturzanfällen, die zu Stürzen und anderen Verletzungen führen können. Die Ergebnisse dieser Studie stellen die einzige gut kontrollierte klinische Bewertung eines Cannabinoid-Medikaments für diese schwere, arzneimittelresistente Erkrankung dar.

“Die Veröffentlichung dieser positiven Ergebnisse ist ein aufregender Meilenstein für die LGS-Community und wir haben guten Grund anzunehmen, dass bald eine neue Behandlungsmöglichkeit zur Verfügung stehen könnte”, sagte Christina SanInocencio, Geschäftsführerin der Lennox-Gastaut Syndrome Foundation. “Für Patienten, die immer noch an unkontrollierten Anfällen leiden, sind dringend zusätzliche Behandlungsmöglichkeiten erforderlich, und diese Ergebnisse bieten denjenigen, die mit dieser schwächenden Erkrankung leben, dringend benötigte Hoffnung.

LGS ist eine der schwierigsten zu behandelnden Arten von Epilepsie und die Mehrheit der Patienten reagieren nicht adäquat auf vorhandene Therapien”, sagte Elizabeth Thiele, MD, PhD, Direktorin für pädiatrische Epilepsie am Massachusetts General Hospital, Professorin für Neurologie an der Harvard Medical School und federführende Autorin der Studienpublikation. “Diese Ergebnisse zeigen, dass Epidiolex klinisch bedeutsame Vorteile für Patienten mit LGS bieten kann.”

Die Studie randomisierte 171 Patienten (86 für CBD (Cannabidiol), 85 für Placebos) im Alter von zwei bis 55 Jahren (Durchschnittsalter 15 Jahre) mit LGS, deren Anfälle nicht durch ihre derzeitige Therapie mit Antiepileptika (AED, Antiepileptic Drugs) kontrolliert wurden, und die dann entweder Cannabidiol (20mg/kg/Tag) oder Placebos zusätzlich zur bestehenden Behandlung erhielten. Bei der in 24 Zentren in den Vereinigten Staaten und Europa durchgeführten Studie nahmen die Patienten durchschnittlich ca. drei Antiepileptika ein, nachdem sie zuvor durchschnittlich sechs andere Antiepileptika ausprobiert und eingestellt hatten. Zu Beginn der Studie hatten die Patienten eine mittlere Häufigkeit von 74 Sturzanfällen pro Monat (Sturzanfälle wurden als atonische, tonische oder tonisch-klonische Anfälle definiert, die den gesamten Körper, Rumpf oder Kopf betreffen und zu einem Sturz, einer Verletzung, Zusammenbrechen auf einem Stuhl oder zum Aufschlagen des Kopfes des Patienten auf einer Oberfläche führten oder hätten führen können).

Während des 14-wöchigen Behandlungszeitraums (ein zweiwöchiger Dosis-Eskalationszeitraum, gefolgt von 12 Wochen Aufrechterhaltung der Dosis) hatten Patienten, die Cannabidiol einnahmen, eine deutlich größere mittlere Verringerung von Sturzanfällen im Vergleich zu Placebos (44 Prozent vs. 22 Prozent; p=0,0135), dem primären Endpunkt der Studie. Sensitivitätsanalysen bestätigten, dass der Behandlungseffekt von Cannabidiol im ersten Monat der Behandlung festgestellt und über den gesamten Behandlungszeitraum beibehalten wurde.

Die Ergebnisse wichtiger sekundärer Endpunkte zeigten, dass wesentlich mehr Patienten mit Cannabidiol im Vergleich zu Placebos eine 50-prozentige oder größere Verringerung von Sturzanfällen erfuhren (44 Prozent vs. 24 Prozent; p=0,0043) und die Häufigkeit der totalen Anfälle mit Cannabidiol im Vergleich zu Placebos deutlich reduziert wurde (mittlere prozentuale Reduktion von 41 Prozent vs. 14 Prozent; p=0,0005). CBD-Patienten/-Betreuer meldeten deutlich öfter eine Verbesserung des Gesamtzustandes mit Cannabidiol als mit Placebos (58 Prozent vs. 34 Prozent; OR 2,54, 95 % CI 1,5-4; p=0,0012), basierend auf der Skala für die Einschätzung der Veränderungen durch den Patienten/Betreuer (S/CGIC-Skala, Subject/Caregiver Global Impression of Change).

Cannabidiol wurde in der Studie im Allgemeinen gut vertragen. Die häufigsten unerwünschten Ereignisse (UEs) (>10 Prozent) waren Durchfall, Schläfrigkeit, Pyrexie, verminderter Appetit und Erbrechen. Insgesamt traten bei 86 Prozent der Patienten, die Epidiolex, und bei 69 Prozent der Patienten, die Placebos einnahmen, unerwünschte Ereignisse ein, von denen die meisten mild oder moderat waren. Von denjenigen Patienten, bei denen unerwünschte Ereignisse auftraten, traten diese Ereignisse gegen Ende der Studie für 61 Prozent der Cannabidiol-Patienten und für 64 Prozent der Placebo-Patienten nicht mehr auf.

Bei zwanzig Patienten, die mit Cannabidiol behandelt wurden, traten schwerwiegende unerwünschte Ereignisse auf, einschließlich eines tödlichen Falls von akutem Atemnotsyndrom (das vom Prüfer als nicht verwandt angesehen wird), verglichen mit schwerwiegenden unerwünschten Ereignisse bei vier Patienten, die mit Placebos behandelt wurden. Zwölf Patienten, die Cannabidiol einnahmen, brachen die Behandlung wegen unerwünschter Ereignisse ab, verglichen mit einem Patienten, der Placebos einnahm.

Im Rahmen des Cannabidiol-Entwicklungsprogramms sind die am häufigsten gemeldeten Nebenwirkungen Somnolenz (Schläfrigkeit), verminderter Appetit, Durchfall, Pyrexie (Fieber), Müdigkeit, Lethargie, Ausschlag, Nasopharyngitis und Pneumonie (Lungenentzündung). Außerdem wurde eine dosisabhängige reversible Erhöhung der Lebertransaminasen ohne Erhöhung des Bilirubins beobachtet.  

“Unkontrollierte Anfälle haben erhebliche Auswirkungen auf das Leben der Patienten und ihrer Familien und es besteht ein enormer Bedarf an neuen Optionen bei schwer behandelbaren Epilepsien wie LGS”, sagte Philip Gattone, Präsident und CEO der Epilepsie-Stiftung. “Diese randomisierte, kontrollierte klinische Studie liefert einen positiven Nachweis für die potenzielle Rolle von Cannabidiol bei der Reduzierung von Anfällen und wir freuen uns über die Möglichkeit einer neuen Behandlungsoption für LGS.”

Informationen zum Lennox-Gastaut-Syndrom   

LGS tritt typischerweise erstmalig im Alter zwischen 3 und 5 Jahren auf. Es kann durch verschiedenen Gesundheitsprobleme verursacht werden, darunter Fehlbildungen des Gehirns, schwere Kopfverletzungen, Infektionen des zentralen Nervensystems und neurodegenerative oder metabolische Störungen. Bei bis zu 30 Prozent der Patienten bleibt die Ursache unentdeckt. Patienten mit LGS leiden in der Regel an verschiedenen Anfallsarten, beispielsweise Sturz- und Krampfanfälle (die häufig zu Stürzen und Verletzungen führen) und krampflose (nicht-konvulsive) Anfälle. Patienten mit LGS weisen häufig eine Therapieresistenz gegenüber Antiepileptika (AED) auf. Bei den meisten Kindern, die an LGS leiden, kommt es zu mehr oder weniger ausgeprägten intellektuellen Beeinträchtigungen sowie Entwicklungsstörungen und anomalen Verhaltensweisen.

Informationen zum Dravet-Syndrom   

Das Dravet-Syndrom ist eine schwere und sehr therapieresistente epileptische Enzephalopathie des frühen Kindesalters, die häufig mit genetischen Mutationen des Natriumkanals SCN1A assoziiert ist. Typischerweise tritt das Dravet-Syndrom erstmalig während des ersten Lebensjahres in zuvor gesunden und entwicklungsmäßig normalen Säuglingen auf. Anfänglich stehen die Krämpfe mit der Körpertemperatur in Verbindung und sind schwerwiegend und langanhaltend. Bei Patienten mit Dravet-Syndrom treten mit der Zeit häufig unterschiedliche Anfallsarten auf, darunter tonisch-klonische Anfälle, myoklonische Anfälle und atypische Absencen. Es besteht häufig eine Neigung zu prolongierten Krampfanfällen, einschließlich des sogenannten Status epilepticus, ein potenziell lebensbedrohlicher Zustand. Für Menschen, die unter dem Dravet-Syndrom leiden, besteht ein erhöhtes Risiko, plötzlich und unerwartet zu sterben, einschließlich SUDEP, ein plötzlich auftretender, ungeklärter Tod bei Epilepsie. Darüber hinaus kommt es bei der Mehrheit der Betroffenen zu moderaten bis schweren intellektuellen Behinderungen und Entwicklungsstörungen, die lebenslange Betreuung und Pflege erforderlich machen. Es gibt derzeit keine von der FDA zugelassenen Therapien, und nahezu alle der Patienten leiden während ihres ganzen Lebens an unkontrollierten Krampfanfällen und benötigen weitere medizinische Hilfe.

Informationen zu Epidiolex® (Cannabidiol)   

Epidiolex, GWs führender Cannabinoid-Produktkandidat, ist eine pharmazeutische Formulierung aus aufbereitetem Cannabidiol (CBD), der sich in der Entwicklung für die Behandlung einer Reihe von seltenen Epilepsie-Erkrankungen befindet, die sich erstmalig im Kindesalter zeigen. GW hat bei der US-amerikanischen FDA einen NDA-Antrag für Epidiolex als Ergänzungstherapie bei Anfallsleiden in Verbindung mit LGS und Dravet-Syndrom eingereicht. Das Zieldatum ist der 27. Juni 2018 und das Arzneimittel soll, falls es genehmigt wird, in der zweiten Hälfte des Jahres 2018 verschreibungspflichtig erhältlich sein. GW hat zudem im Dezember 2017 einen Zulassungsantrag (MAA) bei der Europäischen Arzneimittelagentur EMA eingereicht, dessen Entscheidung für Anfang 2019 erwartet wird. Bis dato hat GW von der FDA die Einstufung für Arzneimittel für seltene Leiden (ODD, Orphan Drug Designation) für Epidiolex zur Behandlung des Dravet-Syndroms, LGS, TSC und IS erhalten. Zusätzlich dazu hat GW von der FDA den Fast Track-Status zur Behandlung des Dravet-Syndroms und den bedingten Status für seltene pädiatrische Erkrankungen erhalten. Von der EMA (Europäische Arzneimittelagentur) hat das Unternehmen den Orphan Drug-Status für Epidiolex zur Behandlung von LGS, Dravet-Syndrom, West-Syndrom und TSC erhalten. GW prüft derzeit weitere klinische Entwicklungsprogramme für andere seltene Anfallsleiden, darunter Phase-III-Studien zu tuberöser Sklerose (TSC) und infantilen Spasmen.

Informationen zu GW Pharmaceuticals plc und Greenwich Biosciences   

Das 1998 gegründete GW ist ein biopharmazeutisches Unternehmen, das sich auf die Erforschung, Entwicklung und Vermarktung von neuartigen Therapeutika auf Basis seiner proprietären Plattform von Cannabinoid-Produkten für ein breites Spektrum von Krankheitsfeldern konzentriert. GW treibt gemeinsam mit seiner Tochtergesellschaft Greenwich Biosciences ein Orphan Drug-Programm voran, das sich der kindlichen Epilepsie widmet. Der Schwerpunkt liegt dabei auf Epidiolex (Cannabidiol), für das GW bei der FDA einen NDA-Antrag als Ergänzungstherapie von LGS und Dravet-Syndrom eingereicht hat. Das Unternehmen prüft Epidiolex bei weiteren Epilepsieindikationen und führt derzeit klinische Prüfungen in Zusammenhang mit tuberöser Sklerose (TSC) und infantilen Spasmen durch. GW hat Sativex® (Nabiximols) kommerzialisiert, das weltweit erste verschreibungspflichtige Medikament auf pflanzlicher Cannabinoid-Basis, das für die Behandlung von Spastik aufgrund von multipler Sklerose in verschiedenen Ländern außerhalb der Vereinigten Staaten zugelassen ist. Das Unternehmen verfügt über eine fundierte Pipeline mit weiteren Cannabinoid-Produktkandidaten, darunter Wirkstoffe, die in Phase-I- und II-Studien für Glioblastom, Schizophrenie und Epilepsie untersucht werden. Weitere Informationen finden Sie unter: http://www.gwpharm.com.

Zukunftsgerichtete Aussagen    

Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, die die gegenwärtigen Erwartungen von GW über zukünftige Ereignisse widerspiegeln, einschließlich Aussagen über die finanzielle Leistungsfähigkeit, die zeitliche Planung von klinischen Studien, die zeitliche Planung und die Ergebnisse von regulatorischen Entscheidungen oder Entscheidungen hinsichtlich des geistigen Eigentums, die Relevanz der im Handel erhältlichen und in der Entwicklung befindlichen GW-Produkte, den klinischen Nutzen von Epidiolex® (Cannabidiol) sowie das Sicherheitsprofil und kommerzielle Potenzial von Epidiolex. Zukunftsgerichtete Aussagen beinhalten Risiken und Unwägbarkeiten.  Tatsächliche Ereignisse können erheblich von den hier getätigten Vorhersagen abweichen und hängen von einer Reihe von Faktoren ab, einschließlich (unter anderem) des Erfolgs der Forschungsstrategien von GW, der Anwendbarkeit der damit einhergehenden Entdeckungen, des erfolgreichen und rechtzeitigen Abschlusses und Unsicherheiten im Zusammenhang mit dem regulatorischen Prozess sowie der Akzeptanz von Sativex, Epidiolex und anderen Produkten durch die Verbraucher und die medizinische Fachwelt. Eine weitere Aufstellung und Beschreibung der Risiken und Unwägbarkeiten im Zusammenhang mit einer Investition in GW finden Sie in den Einreichungen von GW bei der US-amerikanischen Börsenaufsichtsbehörde (SEC), einschließlich des letzten Formulars 20-F, das am 4. Dezember 2017 eingereicht wurde. Bestehende und potenzielle Anleger werden ausdrücklich davor gewarnt, sich vorbehaltlos auf diese zukunftsgerichteten Aussagen zu verlassen, da sie nur zum Datum dieser Mitteilung Gültigkeit haben. GW verpflichtet sich nicht, die in dieser Pressemitteilung enthaltenen Informationen zu aktualisieren oder zu überarbeiten, sei es aufgrund neuer Informationen, zukünftiger Ereignisse oder Umstände oder aus anderen Gründen.

Referenzen:

  1. Thiele EA, Marsh ED, French JA, et al. Cannabidiol (CBD) Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome (LGS): Results of a Multi-center, Randomized, Double-blind, Placebo-controlled Trial (GWPCARE4). Lancet 2017; 376;2011-20.
  2. Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M. Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. J Child Neurol. 2010;25(4):441-447.
  3. LGS Foundation. About Lennox-Gastaut Syndrome (Informationen zum Lennox-Gastaut-Syndrom). Erhältlich von http://www.lgsfoundation.org/aboutlgs. Zugriff am 23. Oktober 2017.
  4. National Institute of Health. Lennox-Gastaut Syndrome. Erhältlich von https://ghr.nlm.nih.gov/condition/lennox-gastaut-syndrome#definition. Zugriff am 23. Oktober 2017.

Anfragen richten Sie bitte an:

GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations
(U.S.) +1-917-280-2424 / +1-401-500-6570

Medienanfragen USA:
Sam Brown Inc. Healthcare
Communications
Christy Curran +1-615-414-8668

Mike Beyer, +1-312-961-2502

Medienanfragen EU:
FTI Consulting
Con Franklin, +44(0)7817-573-659

SOURCE GW Pharmaceuticals

Bailard Recruits Director of Institutional Sales

SAN FRANCISCO–(BUSINESS WIRE)–Bailard, Inc. is pleased to announce that Jeffrey Thornton has joined the firm as senior vice president and director of institutional sales. In this role, Jeff is responsible for expanding Bailard’s business relationships with institutional investors and investment consultants. Jeff will primarily focus on representing Bailard Institutional’s several well-established equity strategies—spanning small value, technology and non-U.S. equities—as well as a core-plus real estate strategy.

“As our institutional strategies continue to garner attention and growth from institutional investors, we need a strong lead to govern our business development efforts,” said Peter M. Hill, Bailard’s chief executive officer. “From overseeing global sales and marketing at RCM Global Investors to his consulting experience, Jeff is a great addition to the team.”

“Bailard’s culture, vetted fundamental and quantitative research processes, track record and growing institutional presence drew me to the company. Bailard has high potential,” said Jeff Thornton. “I look forward to help the firm’s growth accelerate and feel fortunate to be a part of Bailard.”

Before joining Bailard, Jeff was an independent advisor and consultant representing asset managers seeking institutional capital sources. Prior to that, he was head of institutional sales and marketing at LMCG. Previously, Jeffrey spent 14 years at RCM Global Investors (now Allianz Global Investors) as director of marketing and sales. Jeff received his Bachelor’s degree in political science from the University of California, Los Angeles. Outside of work, Jeff is a board member and the treasurer of Big Brothers and Big Sisters for North Lake Tahoe and Nevada County.

About Bailard, Inc.

Founded in 1969, Bailard is a majority employee-owned institutional asset management and wealth advisory firm, entrusted with $4 billion in assets under management. With 67 employees and its headquarters in Foster City, California with a second satellite office in San Francisco, California, Bailard’s core values of openness, fairness, excellence and courage sustain Bailard’s reputation for employee allegiance and client satisfaction.

Bailard Institutional, a division within Bailard, is a discretionary institutional asset manager that offers single asset class strategies ranging from long-only equity and fixed income strategies to alternative strategies and private real estate. Bailard Wealth Management, a division within Bailard, provides investment advisory and financial planning services to investors seeking multi-asset diversification, including a dedicated socially responsible investing service.*

For more information about Bailard, Inc., please visit www.bailard.com or contact Sonya Thadhani, executive vice president and chief operating officer, at (650) 571-5800 or sthadhani@bailard.com.

* All investments involve a risk of loss. There is no guarantee any strategy will achieve its objectives. Bailard will not offer advice in any jurisdiction where it is prohibited from doing so. Real estate and alternative investments have significant specific risks and are not appropriate for all investors.

SouthCrest Financial Group Reports preliminary 4Q17 earnings

ATLANTA, Jan. 24, 2018 (GLOBE NEWSWIRE) — Brian D. Schmitt, Chief Executive Officer of SouthCrest Financial Group, Inc. (SCSG:PK) announced today that the Company reported preliminary results of -$4.59MM or -$0.55/share for the fourth quarter ended December 31, 2017.  Excluding the impact of previously announced one-time items which included the impact of the new tax law and office relocations, net income would have been $0.9MM or $0.11/share.
“Like a large number of our peers, the tax law change created a significant mark to our deferred tax asset.  In addition, we made what we have thought of as a capital investment by preparing to move out of our operations center and to move our Tyrone branch to our Fayetteville LPO.  These two items were responsible for a $5.9MM negative impact to earnings in the fourth quarter. “We were also excited to announce a special dividend of $0.60/common share recently.  At the end of the day, our primary responsibility is to be good stewards of the capital that our investors have given us, and we believe that this was the best use of this capital at this time.   Importantly, we believe that after this dividend the Company has sufficient capital to take advantage of any strategic growth opportunity that may present itself.“The Company should continue to have significant operating leverage, improved loan growth and significantly improved ROA and ROE.”Tangible book value declined to $6.37/share which takes into account both the one-time items and the impact of the special dividend.Deposits saw a normal seasonal pattern for the quarter and were up 15% LQA vs a slight year over year decline of 2%. Total deposits at the end of 4Q17 were $444.7MM vs. $428.9MM as of 3Q17 and $452.7MM as of 4Q16 (adjusted for the Alabama branch sale). On a core basis, expenses for the quarter were $4.2 million, continuing the downward trend that has existed for several quarters.  Total expenses for the quarter were $4.79MM.The estimated Tier 1 Leverage ratio at the end of the quarter for SouthCrest Bank declined to 8.27% due to the funding of the special dividend.  On a fully converted basis (including the conversion of all preferred equity), TBV/share ended the quarter at $6.37 per share.  This metric will continue to be influenced by OCI changes resulting from the swings in interest rates. Currently, the negative impact to TBV by OCI is -$0.19/share vs. -$0.07/share as of 3Q17. The current fully converted share count at the end of the quarter remained 8.41 million shares. In addition, the Company still retains a small deferred tax asset valuation allowance related to state taxes that totals approximately $0.07/fully converted share.Asset quality remained steady during the quarter, with NPAs to assets ticking up slightly to 1.05% from 0.91%, excluding the $2.5 million of former bank buildings that are projected to be sold over the next several quarters in OREO.  Including these buildings, 3Q17 NPAs/total assets were 1.51% of assets vs. 1.28% in 3Q17, with half of the increase being driven by the operations center that is being vacated. Excluding the impact of the Bank buildings in OREO, OREO balances were just $115,000.   ABOUT SOUTHCRESTSouthCrest Financial Group, Inc. is a bank holding company with over half a billion dollars in assets, headquartered in Atlanta, GA.  The company operates a 9 branch network throughout Georgia through its subsidiary bank, SouthCrest Bank, N.A.  The bank provides a full suite of retail, private, entrepreneurial, high-net-worth and commercial banking services, and online banking services. FORWARD LOOKING STATEMENTSThis presentation may contain certain “forward-looking statements” that are subject to risks, uncertainties, and other factors that could cause actual results and shareholder values to differ materially from those projected.  Factors that could cause or contribute to such differences include economic conditions, government regulation and legislation, changes in interest rates, credit quality, competition, and other risk factors. Contact:
Andy Borrmann
Chief Financial Officer
678.734.3505
Andrew Bowen, APR
ab@clearviewcom.com
404-822-3309 

Grupo Financiero Interacciones reports net income of Ps.2,940 million for the full year of 2017, up 13.25% YoY

MEXICO CITY, Jan. 24, 2018 /PRNewswire/ — Grupo Financiero Interacciones, S.A.B. de C.V., (BMV: GFINTERO), (“Grupo Financiero Interacciones” or “GFI”), the largest specialized Mexican financial group with a business model focused on providing financing, risk management and financial advisory services mainly to the Mexican public sector, today announced results for the three and twelve month periods ended December 31, 2017.

To obtain the full text of this earnings release, please visit http://www.investorsinteracciones.com/images/media/quartelyResults/2017/4Q17/4Q17_Earnings_Release_Ingles_VF.pdf

Executive Summary: Simplified Financial Information (“SFI”)

Disclaimer: As a result of the uniqueness of our business model, we simplified GFI´s financial information in an effort to make it more efficient to market participants to analyze our financial group. Simplified Financial Information (“SFI”) is adjusted for valuations effects, non-recurring items and includes reclassifications of regulatory financial statements.

Fundamentals

  • GFI´s fundamentals were centered entirely on the surplus in liquidity that states and municipalities exhibited for the duration of the year; this liquidity resulted in part from the annual twelve month federal transfer growth of 11.2%, which prompted states and municipalities to make payments on their existing loans.

During the year, states and municipalities presented a liquidity surplus ranging from 16.4% in 1Q17 to a 3.2% deficit in 4Q17, in contrast with a 6.9% liquidity deficit in 4Q16. Total payments amounted to Ps.127 billion for the year, which represented a 32.6% increase relative to 2016. GFI successfully reconstituted 1.1x its loan portfolio by absorbing the observed commercial activity during the year and focused on higher yielding assets, while lowering its total cost of funds through diversification, to deliver the loan growth shown on its balance sheet by the end of the year.

Please note that GFI was able to maintain an average loan growth of 18% relative to 2016, however, given the higher than expected subnational liquidity levels that resulted in the aforementioned increase in payments during the year, GFI reported a balance of Ps.116,807 million by the end of the year, up 1.54% YoY and 10.23% QoQ.

Simplified Financial Statements

Grupo Financiero Interacciones

Simplified Financial Information (“SFI”)

4Q17

3Q17

4Q16

Var.vs 

 12M17 

 12M16 

Var.vs

3Q17

4Q16

 12M16 

     Bank – Interest Income

3,027

2,982

2,261

1.51%

33.88%

11,640

7,792

49.38%

     Bank – Interest Expense

-2,159

-2,204

-1,651

-2.04%

30.77%

-8,682

-5,381

61.35%

Bank´s Financial Margin

868

778

610

11.57%

42.30%

2,958

2,411

22.69%

     Provisions for Loan Losses

-269

70

-367

-484.29%

-26.70%

-244

151

-261.59%

     Net Commissions

848

740

971

14.59%

-12.67%

2,705

2,315

16.85%

Business Commissions

594

804

628

-26.12%

-5.41%

2,200

2,143

2.66%

Temporary Commissions

254

-64

343

-496.88%

-25.95%

505

172

193.60%

     Income from Brokerage Activities

22

39

167

-43.59%

-86.83%

401

323

24.15%

     Other Operating Income (Expenses)

-22

13

94

-269.23%

-123.40%

-68

-38

78.95%

     IPAB

-123

-123

-104

0.00%

18.27%

-489

-403

21.34%

     Administrative and Promotional Expenses (“SG&A”)

-599

-577

-527

3.81%

13.66%

-2,157

-1,753

23.05%

Subsidiary Result

2

2

0.00%

100.00%

4

4

0.00%

Bank´s Income before Income Taxes

727

942

844

-22.82%

-13.86%

3,110

3,010

3.32%

Brokerage Unit´s Income before Income Taxes

73

59

85

23.73%

-14.12%

402

261

54.02%

Insurance Unit´s Income before Income Taxes

111

3

45

3600.00%

146.67%

110

46

139.13%

Extraordinary Items

-136

0

0

100.00%

100.00%

-136

100.00%

Other Subsidiary Results

-12

-5

100.00%

140.00%

-33

-12

175.00%

     Taxes

-96

-162

-179

-40.74%

-46.37%

-513

-709

-27.64%

Net Income

667

842

790

-20.78%

-15.57%

2,940

2,596

13.25%

* Millions of pesos

*Simplified Financial Information (“SFI”) is adjusted for valuations effects, non-recurring items and includes reclassifications of regulatory financial statements

Main Indicators – Simplified Financial Information (“SFI”)

4Q17

3Q17

4Q16

Var.vs 

 12M17 

 12M16 

 Var. vs
12M16 

3Q17

4Q16

Main Financial Ratios

Bank – Loan Portafolio Financial Margin 

3.12%

2.97%

2.40%

15bp

73bp

2.55%

2.27%

28bp

ROE – Bank

18.19%

22.85%

21.06%

-466bp

-287bp

18.84%

18.95%

-11bp

ROE – GFI

16.12%

21.24%

20.58%

-512bp

-446bp

18.09%

17.52%

57pb

Bank´s Efficiency Ratio

42.07%

44.59%

34.26%

-251bp

782bp

44.13%

43.03%

110bp

NPL Ratio

0.02%

0.05%

0.05%

-3bp

-3bp

0.02%

0.05%

-3bp

Coverage Ratio

62.41x

26.25x

25.77x

36.16x

26.25x

62.41x

25.77x

36.64x

*Millions of pesos

*Simplified Financial Information (“SFI”) is adjusted for valuations effects, non-recurring items and includes reclassifications of regulatory financial statements

  • The Bank´s financial margin for 4Q17 increased 42.30% YoY and 11.57% QoQ. The YoY change resulted from the positive contribution from GFI´s loan book as it was reconstituted during the year with a higher weighting in infrastructure banking products, which have higher yields, while lowering the cost of funds. The QoQ change is mainly explained by a 10.23% expansion in the loan portfolio in addition to a 2.04% decrease in interest expense.
  • During 4Q17, GFI provisioned Ps.269 million, mainly as a result of the change in the portfolio mix, as well as in the credit profile of GFI´s clients during both time periods.
  • Net Commissions decreased 12.67% YoY and increased 14.59% relative to 3Q17. The YoY change reflects the effect of higher liquidity levels in states and municipalities, despite the positive performance at the Infrastructure banking unit.

    The sequential growth reflects higher short-term lending at the Government banking unit, on the back of a 176.47% expansion in loan originations in this business line, as well as GFI´s prioritization on Infrastructure Banking products, which represent higher yielding assets relative to other commercial lines.

    Please note that advisory commissions on hedging solutions for GFI´s clients are registered in the “Income from Brokerage Activities” line as per accounting guidelines on regulatory financial statements.

  • Income from Brokerage Activities amounted to Ps.22 million in 4Q17, representing a decrease of 86.83% YoY and 43.59% QoQ. These changes are explained by better profit making opportunities during both prior time periods.
  • Other Operating Income (Expenses) amounted to Ps.22 million expense in 4Q17, compared to other operating income of Ps.94 million in 4Q16 and Ps.13 million in 3Q17. This line includes changes in Other Real Estate Owned (“OREO”) and OREO discount adjustments, among others.
  • Administrative and Promotional Expenses (SG&A) increased 13.66% YoY and 3.81% QoQ mainly driven by legal services related to the structuring of infrastructure banking projects, as GFI structured 37% more worth of contracts throughout 2017.
  • The Brokerage Unit reported income before taxes of Ps.73 million in 4Q17, decreasing 14.12% YoY and increasing 23.73% QoQ. The YoY change reflects a 9.88% increase in SG&A as well as a decrease in other income, which more than offset the 6.61% increase in commissions and the 57.33% increase in trading income, while the QoQ increase is explained by a 44.94% higher revenue from commissions.
  • Aseguradora Interacciones, the Insurance unit, reported income before taxes of Ps.111 million in 4Q17, compared to Ps.45 million in 4Q16 and Ps.3 million in 3Q17. Both changes are mainly explained by a Ps.204 million catastrophic reserve release due to a change in the methodology in the calculation of this reserve, in addition to a technical reserve release related with the non-renewal of Property & Casualty businesses with a much higher risk exposure, in line with this unit´s strategy of aligning its costs to revenues.
  • Extraordinary Items amounted to Ps.136 million, these expenses are a result of legal fees regarding the recent transaction with GFNORTE announced on October 25th 2017, as well as for the cancellation of prepaid expenses related to issuances that will no longer be required.
  • Grupo Financiero Interacciones reported net income of Ps.667 million in 4Q17, representing a decrease of 15.57% YoY and 20.78% QoQ. The YoY decrease is mainly explained by 12.67% lower net commissions (“SFI”) at the Bank reflecting the effect of higher liquidity levels in states and municipalities in addition to the extraordinary items mentioned above, which more than offset the 42.30% expansion in financial margin (“SFI”) at the Bank as well as the 146.67% increase in the Insurance Unit´s income before taxes. The QoQ change reflects a Ps.339 million increase in provisions for loan losses given a change in GFI´s portfolio mix and its client´s credit profiles in addition to the aforementioned extraordinary items, which more than offset the increases of 11.57% in financial margin (“SFI”), 14.59% in net commissions (“SFI”), as well as a Ps.108 million increase in the Insurance Unit´s income before taxes during this time period.

    Despite the extraordinary items and the provision dynamics mentioned above, GFI reported net income for full year 2017 of Ps.2,940 million, up 13.25% YoY.

REGULATORY FINANCIAL STATEMENTS – Income Statement

Grupo Financiero Interacciones

Regulatory Income Statement

4Q17

3Q17

4Q16

Var.vs 

 12M17 

 12M16 

Var.vs

3Q17

4Q16

 12M16 

     Interest Income

4,491

4,309

3,595

4.22%

24.92%

17,591

12,309

42.91%

     Premium Income (Net) 

52

22

19

136.36%

173.68%

92

183

-49.73%

     Interest Expense

-3,272

-3,502

-2,704

-6.57%

21.01%

-14,921

-9,118

63.64%

     Net Increase in Technical Reserves

204

-3

99

-6900.00%

106.06%

195

90

116.67%

     Damages, Claims and Other Obligations (Net) 

-4

-12

-14

-66.67%

-71.43%

-24

-120

-80.00%

Financial Margin

1,471

814

995

80.71%

47.84%

2,933

3,344

-12.29%

     Provisions for Loan Losses

-249

55

-552.73%

100.00%

-249

-1

-24800.00%

Financial Margin Adjusted for Credit Risk

1,222

869

995

40.62%

22.81%

2,684

3,343

-19.71%

          Commissions and Fees Charged

1,667

987

1,286

68.90%

29.63%

4,299

4,662

-7.79%

          Commissions and Fees Paid

-433

-241

-166

79.67%

160.84%

-1,074

-1,452

-26.03%

     Commissions (Net)

1,234

746

1,120

65.42%

10.18%

3,225

3,210

0.47%

     Income from Brokerage Actiities

-115

508

-21

-122.64%

447.62%

1,848

-7

-26500.00%

     Other Operating Income (Expenses)

-508

-246

-270

106.50%

88.15%

-807

-379

112.93%

     Administrative and Promotional Expenses

-1,072

-875

-857

22.51%

25.09%

-3,501

-2,868

22.07%

Operating Income

761

1,002

967

-24.05%

-21.30%

3,449

3,299

4.55%

     Equity in Results of Non-Consolidated Subsidiaries and Associates

2

2

1

0.00%

100.00%

4

5

-20.00%

Income before Income Taxes

763

1,004

968

-24.00%

-21.18%

3,453

3,304

4.51%

     Income Taxes

-270

-300

-170

-10.00%

58.82%

-887

-661

34.19%

     Deferred Income Taxes

174

138

-8

26.09%

-2275.00%

374

-47

895.74%

Income Before Discontinued Operations

667

842

790

-20.78%

-15.57%

2,940

2,596

13.25%

     Discontinued Operations

0.00%

0.00%

0.00%

Net Income

667

842

790

-20.78%

-15.57%

2,940

2,596

13.25%

     Non-Controlling Interest

0.00%

0.00%

0.00%

Total Net Income

667

842

790

-20.78%

-15.57%

2,940

2,596

13.25%

* Millions of pesos

REGULATORY FINANCIAL STATEMENTS – Main Indicators

Main Indicators – Regulatory Income Statement

4Q17

3Q17

4Q16

Var.vs 

 12M17 

 12M16 

 Var. vs
12M16 

3Q17

4Q16

Main Financial Ratios

NIM

2.65%

1.51%

1.84%

114pb

81pb

1.24%

1.53%

-29pb

ROE – Bank

18.19%

22.85%

21.06%

-466pb

-287pb

18.84%

18.95%

-11pb

ROE -GFI

16.12%

21.24%

20.58%

-512pb

-446pb

18.09%

17.52%

57pb

Bank´s Efficiency Ratio

43.34%

44.16%

42.78%

-82pb

56pb

44.31%

41.76%

255pb

Efficiency Ratio – GFI

51.49%

48.02%

46.98%

347pb

451pb

48.63%

46.50%

213pb

NPL Ratio

0.02%

0.05%

0.05%

-3pb

-3pb

0.02%

0.05%

-3pb

Coverage Ratio

62.41x

26.25x

25.77x

36.16x

36.63x

62.41x

25.77x

36.63x

*Millions of pesos

*Normalized NIM” has been put on the Main Indicators table, to account for the changes in interest income and interest expense, 

as a result of the volatility in the USD/MXN exchange rate and UDIs

REGULATORY FINANCIAL STATEMENTS – Balance Sheet

Grupo Financiero Interacciones

Regulatory Balance Sheet

4Q17

3Q17

4Q16

Var.vs 

 12M17 

 12M16 

Var.vs

3Q17

4Q16

 12M16 

Cash and Due from Banks

10,102

7,527

12,929

34.21%

-21.87%

10,102

12,929

-21.87%

Margin Accounts

0.00%

0.00%

0.00%

Investment in Securities

114,048

87,796

105,398

29.90%

8.21%

114,048

105,398

8.21%

Debtors Under Sale and Repurchase Agreements

57

0.00%

-100.00%

57

-100.00%

Derivatives

561

627

101

-10.53%

455.45%

561

101

455.45%

Total Loan Portoflio (Net)

115,122

104,518

113,565

10.15%

1.37%

115,122

113,565

1.37%

Loan Portfolio

116,807

105,962

115,034

10.23%

1.54%

116,807

115,034

1.54%

Performing Loan Portfolio

116,780

105,907

114,977

10.27%

1.57%

116,780

114,977

1.57%

Commercial Loans

116,383

105,753

114,798

10.05%

1.38%

116,383

114,798

1.38%

                         Commercial or Business Activity

28,458

27,059

24,793

5.17%

14.78%

28,458

24,793

14.78%

                         Financial Entities

1,456

760

487

91.58%

198.97%

1,456

487

198.97%

                         Government Entities

86,469

77,934

89,518

10.95%

-3.41%

86,469

89,518

-3.41%

Consumer Loans

270

19

21

1321.05%

1185.71%

270

21

1185.71%

Mortgages

127

135

158

-5.93%

-19.62%

127

158

-19.62%

Non-Performing Loan Portfolio

27

55

57

-50.91%

-52.63%

27

57

-52.63%

Commercial Non-Performing Loans

22

50

50

-56.00%

-56.00%

22

50

-56.00%

Commercial or Business Activity

22

50

50

-56.00%

-56.00%

22

50

-56.00%

Government Entities

0.00%

0.00%

0.00%

Non-Performing Mortgages

5

5

7

0.00%

-28.57%

5

7

-28.57%

Allowances for Loan Losses 

-1,685

-1,444

-1,469

16.69%

14.70%

-1,685

-1,469

14.70%

Accounts Receivables Loan Derivatives, Discounts and Credits (Net)

3

3

3

0.00%

0.00%

3

3

0.00%

Premium Debtors (Net)

60

20

74

200.00%

-18.92%

60

74

-18.92%

Accounts Receivables from Reinsurers and Re-guarantee Companies (Net)

444

576

1,063

-22.92%

-58.23%

444

1,063

-58.23%

Accounts Receivables (Net)

4,035

5,107

3,605

-20.99%

11.93%

4,035

3,605

11.93%

Foreclosed Assets (Net)

133

146

175

-8.90%

-24.00%

133

175

-24.00%

Real Estate, Furniture & Equipment (Net)

725

732

759

-0.96%

-4.48%

725

759

-4.48%

Investment in Subsidiaries

73

70

61

4.29%

19.67%

73

61

19.67%

Deferred Taxes (Net)

1,199

1,009

841

18.83%

42.57%

1,199

841

42.57%

Other Assets

626

744

1,437

-15.86%

-56.44%

626

1,437

-56.44%

Total Assets

247,131

208,875

240,068

18.32%

2.94%

247,131

240,068

2.94%

Traditional Funding

104,203

102,630

101,096

1.53%

3.07%

104,203

101,096

3.07%

          Demand Deposits

58,975

62,429

49,643

-5.53%

18.80%

58,975

49,643

18.80%

          Term Deposits

26,630

21,707

34,798

22.68%

-23.47%

26,630

34,798

-23.47%

          Credit Instruments Issued

18,598

18,494

16,655

0.56%

11.67%

18,598

16,655

11.67%

Bank Loans

25,181

16,050

18,936

56.89%

32.98%

25,181

18,936

32.98%

          Instant Loans Flexibility

590

880

500

-32.95%

18.00%

590

500

18.00%

          Short Term

10,008

3,930

7,199

154.66%

39.02%

10,008

7,199

39.02%

          Long Term

14,583

11,240

11,237

29.74%

29.78%

14,583

11,237

29.78%

Assigned Values For Liquidity

0.00%

0.00%

0.00%

Technical Reserves

711

959

1,495

-25.86%

-52.44%

711

1,495

-52.44%

Creditors For Repurchase / Resale Agreements

91,783

63,950

93,597

43.52%

-1.94%

91,783

93,597

-1.94%

Collateral Sold

499

0.00%

-100.00%

499

-100.00%

Derivatives

232

146

457

58.90%

-49.23%

232

457

-49.23%

Valuation Ajustment For Financial Coverage Of Liabilities

0.00%

0.00%

0.00%

Accounts Payables To Reinsurers And Re-Guarantee Companies

64

10

211

540.00%

-69.67%

64

211

-69.67%

Outstanding Debt In Securitization Transactions

0.00%

0.00%

0.00%

Other Payables

4,870

4,652

3,643

4.69%

33.68%

4,870

3,643

33.68%

Outstanding Subordinated Debt

2,860

3,565

3,561

-19.78%

-19.69%

2,860

3,561

-19.69%

Deferred Taxes And Employee Profits Sharing (Net)

13

28

16

-53.57%

-18.75%

13

16

-18.75%

Deferred Credits And Advanced Collections

390

617

882

-36.79%

-55.78%

390

882

-55.78%

Total Liabilities

230,307

192,607

224,393

19.57%

2.64%

230,307

224,393

2.64%

Paid-In Capital

4,213

4,213

4,205

0.00%

0.19%

4,213

4,205

0.19%

               Capital Stock

2,345

2,345

2,344

0.00%

0.04%

2,345

2,344

0.04%

               Share Subscription Premiums 

1,868

1,868

1,861

0.00%

0.38%

1,868

1,861

0.38%

Subscribed Capital

12,611

12,054

11,470

4.62%

9.95%

12,611

11,470

9.95%

               Capital Reserves

801

801

671

0.00%

19.37%

801

671

19.37%

               Retained Earnings

8,667

8,667

7,922

0.00%

9.40%

8,667

7,922

9.40%

               Surplus (deficit) from Mark-to-Market of Securities Available for Sale 

223

310

276

-28.06%

-19.20%

223

276

-19.20%

               Foreign currency translation adjustment

5

4

5

25.00%

0.00%

5

5

0.00%

               Results from Non-monetary Assets

-25

-1

2400.00%

-100.00%

-25

-100.00%

               Net Income with Participation of Subsidiaries

2,940

2,273

2,596

29.34%

13.25%

2,940

2,596

13.25%

 Not Holding Interest

1

1

0.00%

100.00%

1

100.00%

Shareholders’ Equity

16,825

16,268

15,675

3.42%

7.34%

16,825

15,675

7.34%

* Millions of pesos

RELEVANT EVENTS

  • GRUPO FINANCIERO INTERACCIONES, S.A.B. DE C.V. (“GFINTER”) hereby informs that on October 25, 2017, GRUPO FINANCIERO BANORTE, S.A.B. DE C.V. (“GFNORTE”), entered into a master merger agreement pursuant to which GFINTER will merge into GFNORTE. The merger and the effects of the Master Merger Agreement were approved by the shareholders of both issuers, gathered at general extraordinary meetings on December 5, 2017. Approval by the financial and economic competition authorities (anti-trust) is still pending.
  • During 4Q17 GFINTER incurred in extraordinary expenses that amounted to Ps.136 million. These expenses are a result of legal fees regarding the recent transaction with GFNORTE, as well as for the cancellation of prepaid expenses related to issuances that will no longer be required.

4Q17 EARNINGS CONFERENCE CALL

Date: Thursday, January 25, 2018

Time: 9:00 am CT (Mexico), 10:00 am ET

The conference call can be accessed by dialing +1-844-824-3835 (U.S.A. / Canada), 001-855-817-7630 (Mexico), or +1-412-317-5160 (Other International) and asking to be joined into the Grupo Financiero Interacciones call. The earnings release for the fourth quarter ending December 31, 2017 will be issued after the close of the U.S. market on Wednesday, January 24, 2018.

A simultaneous webcast of the conference call can be accessed by clicking the following link: https://www.webcaster4.com/Webcast/Page/1449/24051

A telephonic replay of the conference call will be available after 12:00pm on January 26, 2018 on GFI’s Investor Relations website at www.investorsinteracciones.com.

About Grupo Financiero Interacciones

Grupo Financiero Interacciones, S.A. de C.V. (“Grupo Financiero Interacciones” or “GFI”), is the largest specialized Mexican financial group with a business model focused on providing financing, risk management and financial advisory services mainly to the Mexican public sector, which includes federal, state and municipal governments, quasi-government entities and government suppliers. Grupo Financiero Interacciones conducts its business mainly through Banco Interacciones, its banking subsidiary, and through Interacciones Casa de Bolsa, its broker-dealer subsidiary, and Aseguradora Interacciones, its insurance company subsidiary. Grupo Financiero Interacciones is listed on the Bolsa Mexicana de Valores under the symbol “GFINTERO”. For more information, please visit http://www.investorsinteracciones.com

This press release contains forward-looking statements and information that are necessarily subject to risks, uncertainties, and assumptions. By their very nature, forward-looking statements and such information involve inherent risks and uncertainties, both general and specific, and risks exist that the predictions, forecasts, projections and other forward-looking statements will not be achieved or will differ from actual results. A number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed or implied in such forward-looking statements. Should one or more of these factors or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected or intended. Grupo Interacciones assumes no obligation to update or correct the information contained in this press release.

Contact:
Adolfo Werner Fritz Rubio, Corporate Development Officer & Head of Investor Relations
Telephone: +52 55 53 26 86 00 Ext: 6825
E-mail: iro@interacciones.com

Cision View original content:http://www.prnewswire.com/news-releases/grupo-financiero-interacciones-reports-net-income-of-ps2940-million-for-the-full-year-of-2017-up-1325-yoy-300587933.html

SOURCE Grupo Financiero Interacciones, S.A. de C.V.

Related Links

http://www.grupofinancierointeracciones.mx/

Kimbal Riley será o diretor executivo do Vista Group

AUCKLAND, Nova Zelândia–(BUSINESS WIRE)–Vista Group International (NZX & ASX: VGL) anunciou hoje que Kimbal Riley assumirá o cargo de diretor executivo do Grupo, antes ocupado por Murray Holdaway. Holdaway assumirá a posição de diretor de produtos (Chief Product Officer, CPO) do Vista Group, e continuará com seu papel de diretor executivo no conselho do Vista Group. Essa alteração faz parte de um processo de planejamento de sucessão e promoverá uma transição suave no negócio.

Riley teve uma carreira extensa em papéis executivos sêniores no setor de TI e de Serviços Industriais na Nova Zelândia e em outros países. Ele se juntou ao Vista Group há quatro anos, e passou os últimos dois anos como diretor executivo do Vista Entertainment Solutions (VES), responsável pela maior parte da receita do Grupo. Seu foco esteve em otimizar as receitas e os recursos do negócio, e, sob sua liderança, o VES aumentou sua presença global em 20 novos mercados, estendendo seu alcance para mais de 80 países. O VES continuou sustentando um crescimento de receita de 20% ao ano sob a liderança do Riley, e tem sido a maior fonte de crescimento que ajudou a abrir outras oportunidades de mercado internacional para os negócios do Grupo.

Kirk Senior, presidente do Vista Group, homenageou Holdaway por sua liderança excepcional na empresa, cofundada por ele em 1996. O Vista cresceu e se tornou um fornecedor dominante nas áreas de gestão de cinema, distribuição de filmes e softwares de análise de clientes na indústria cinematográfica global. Suas empresas subsidiárias fornecem produtos e serviços para vários segmentos da indústria cinematográfica.

“Murray mostrou uma ótima visão e especialidade em liderar uma equipe para criar e para crescer o Vista Group, uma das empresas de tecnologia com melhor desempenho da Nova Zelândia. Suas forças continuam em inovação de produtos e serviços ao cliente, e, com a diversificação do Vista desde que ouvimos o público em 2014, queremos que ele supervisione a área para a qual ele agregou mais valor: inovação de produtos. Essa é a base do sucesso do Grupo, o coração e a alma do que fazemos”, disse Kirk Senior.

“Agora, após mais de duas décadas construindo e liderando o Vista Group, é hora dele entregar as rédeas da liderança para Kimbal Riley, seu sucessor natural. Temos muita sorte por mantermos o conhecimento e os pontos fortes essenciais de Murray em seu papel como diretor de produtos.”

Riley disse que está honrado por ter a oportunidade de ser o diretor executivo do Vista Group, que está preparado para o próximo estágio de sua evolução, e está encantado por trabalhar junto com o seu cofundador visionário.

“Entre todos do negócio, Murray é um dos que mais tem conhecimento sobre os dados e o fluxo de informações da indústria cinematográfica entre todos do negócio. A empresa tem vários desafios emocionantes à frente, a medida em que continuamos desenvolvendo softwares líderes mundiais que fornecem inovação para cinemas e distribuidores. Isso desbloqueará o potencial para grandes percepções de dados que criarão experiências mais emocionantes para os cinéfilos. Gosto de ajudar a construir negócios e, com alguém como Murray como visionário de produtos, o trabalho se torna duas vezes mais emocionante.”

Holdaway disse que está ansioso para assumir seu papel como diretor de produtos, o que permitirá que ele apoie o diretor executivo do Vista Group e suas equipes trabalhando nos setores de produto da empresa para aumentar a inovação e expandir ofertas para a sua base de clientes global.

“Esta transição vem em um momento importante do nosso desenvolvimento, quando algumas das empresas do Grupo estão prontas para introduzirem novas ofertas de produtos e serviços na indústria. À luz disso, apoiar o desenvolvimento e a execução de produtos é essencial; estarei focado na direção de produtos do Grupo em um momento em que várias novas mudanças de geração significativas estão acontecendo nas empresas, a medida em que evoluem seus produtos para atenderem às necessidades dos nossos clientes e ampliarem o mercado.”

“Gostaria de aproveitar esta oportunidade para agradecer a todos que me apoiaram como diretor executivo nos últimos 22 anos. Temos uma equipe apaixonada e talentosa no Vista Group, e tem sido um privilégio poder liderá-la.”

A mudança na liderança será efetiva a partir de 3 de abril de 2018, quando Riley se tornará o diretor executivo do Vista Group e Holdaway assumirá o papel de diretor de produtos.

Sobre o Vista Group International:

O Vista Group International (Vista Group) é uma empresa pública, listada nas bolsas de valores da Nova Zelândia e da Austrália (NZX & ASX: VGL). O Grupo forneceu soluções tecnológicas adicionais e de software em toda a indústria cinematográfica global. O software de gestão de cinema é fornecido pelo Vista Entertainment Solutions (Vista Cinema), o negócio principal do Grupo. Movio (autoridade em análise de dados de cinéfilos), Veezi (software SaaS com base na nuvem para o mercado de cinema independente), movieXchange (conectando a indústria de cinema para simplificar a promoção e a venda de ingressos de cinema), Maccs (software de distribuição de filmes), Numero (software de relatório de bilheteria para distribuidores de filmes e cinemas), Cinema Intelligence (soluções de inteligência de negócios), Powster (plataforma de marketing e estúdio multidisciplinar para estúdios de filmes), e Flicks (portal de informações de filmes para cinéfilos) fornecem uma variedade inovadora de produtos complementares em diversos outros setores da indústria cinematográfica, desde a produção e distribuição, à exibição nos cinemas e experiência dos cinéfilos. O Vista Group tem escritórios na Nova Zelândia (Auckland HQ), Sydney, Los Angeles, Londres, Xangai, Pequim, Cidade do México, África do Sul, Países Baixos e Romênia.
Site: www.vistagroup.co
LinkedIn: www.linkedin.com/company/vista-group-limited

Sobre o Vista Entertainment Solutions:

Vista Entertainment Solutions Ltd (Vista Cinema) é um dos líderes mundiais de soluções de software para gestão de cinema com instalações em mais de 80 países em todo o mundo, e uma participação de mercado global de 38% no mercado do grande circuito de cinema. A linha de produtos de software do Vista Cinema abrange vários módulos, integrados e escaláveis, adequados para expositores de cinema que operam mais de 20 telas e centenas de cinemas. O Vista Cinema tem sede em Auckland, Nova Zelândia, e tem subsidiárias incorporadas em Los Angeles, Londres, Xangai, Pequim, Cidade do Cabo e Cidade do México.
Website: www.vista.co
Twitter: @VistaCinema
LinkedIn: www.linkedin.com/company/vista-entertainment-solutions

O texto no idioma original deste anúncio é a versão oficial autorizada. As traduções são fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que é a única versão do texto que tem efeito legal.